Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

221. Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Full Text available with Trip Pro

and effective in children with bipolar disorder and comorbid ADHD after stabilisation of manic symptoms with divalproex sodium? METHODS Design: Randomised controlled crossover trial. Allocation: Not stated. Blinding: Double blind. Follow up period: Two weeks randomised treatment; 12 weeks open label follow up. Setting: One hospital in Dallas, Texas, USA. Patients: Thirty one children (mean age 9.8 years) with DSM-IV diagonosed bipolar I or II disorder and attention deficit hyperactivity disorder (ADHD (...) benefit countless children and adolescents whose functioning is compromised by not one, but two serious psychiatric conditions. References Biederman J, Mick E, Prince J. et al . Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder J Child Adolesc Psychopharmacol 1999 ; 9 : 247 –56. Faraone SV, Biederman J, Wozniak J. et al . Is comorbidity with ADHD a marker for juvenile-onset mania? J Am Acad Child Adolesc

2006 Evidence-Based Mental Health

222. Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD Full Text available with Trip Pro

for ADHD in stimulant responsive children? METHODS Design: Randomised controlled trial. Allocation: Not reported. Blinding: Phase 1 unblinded; phase 2 participants blinded to placebo substitution. Follow up period: 24 months. Setting: Two medical centres, New York and Montreal. Patients: 103 children aged 7–10 years with DSM-III attention deficit/hyperactivity disorder (ADHD) who had previously responded to methylphenidate; ⩾1.5 on hyperactivity index of Conners’ teacher rating scale; medication free (...) Am Child Adolesc Psychiatry 2004 ; 43 : 792 –801. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999 ; 56 : 1073 –86. Footnotes For correspondence: Dr Abikoff, NYU Child Study Centre, 215 Lexington Avenue, 13th Floor, New York, NY 10016, USA Sources of funding: NIMH grant. Request Permissions If you wish to reuse any or all of this article please use the link below which will take you

2006 Evidence-Based Mental Health

223. Attention deficit

Attention deficit Attention deficit | The King's Fund Main navigation Health and care services Leadership, systems and organisations Patients, people and society Policy, finance and performance Search term Apply Attention deficit This content relates to the following topics: Share this content Authors Niall Dickson '£1bn in the red!' 'Thousands of NHS staff to be axed!' These are just a couple of the numerous headlines this week that sum up the mounting pressure on the health service (...) at the moment. But, as we reach the end of the financial year, there could be even more stories of deficits, wards being closed and staff being cut. Basically the unwelcome headline has returned – with a vengeance. The former prime minister Harold Macmillan once referred to the pressure of 'events, dear boy, events'. Well, we have had more than our share of events already in 2006. The sudden departure of Sir Nigel Crisp as NHS chief executive and permanent secretary of the Department of Health, larger-than

2006 The King's Fund

224. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98) Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents | Guidance | NICE Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents Technology appraisal guidance [TA98] Published date: 22 March 2006 Guidance This guidance has

2006 National Institute for Health and Clinical Excellence - Technology Appraisals

225. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

and the authors' conclusions are likely to be reliable. Authors' objectives To assess the clinical and cost-effectiveness of methylphenidate (MPH), dexamfetamine sulfate (DEX) and atomoxetine (ATX) in children and adolescents diagnosed with attention deficit hyperactivity disorder (ADHD). Searching The authors searched ten databases (listed) for published literature; the search strategies used were reported. The searches were conducted in July 2004 and no language restrictions were imposed. Only studies (...) A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model

2006 DARE.

226. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder

and control group were eligible for inclusion. Specific interventions included in the review Studies comparing immediate-release methylphenidate with placebo were eligible for inclusion. The majority of the included studies used a single dose immediate-release methylphenidate that was not varied based on patient characteristics. Participants included in the review Studies of children who met formal diagnostic criteria for ADHD or attention-deficit disorder, or who were described as hyperactive (...) Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Pietrzak R H, Mollica C M, Maruff P, Snyder P J CRD summary This review assessed the cognitive effects of immediate-release methylphenidate in children

2006 DARE.

227. Parent involvement in treatment for ADHD: a meta-analysis of the published studies

Parent involvement in treatment for ADHD: a meta-analysis of the published studies Parent involvement in treatment for ADHD: a meta-analysis of the published studies Parent involvement in treatment for ADHD: a meta-analysis of the published studies Corcoran J, Dattalo P CRD summary This review assessed the effect of parent-involved psychosocial interventions in the treatment of children with attention deficit/hyperactivity disorder (ADHD). The authors concluded that family interventions have (...) a low to moderate effect on ADHD and externalising symptoms, but a moderate effect on child-internalising symptoms. Limitations of the analysis and uncertain quality of the included studies restrict interpretation of the results. Authors' objectives The primary objective was to determine the effect of parent-involved psychological treatment for attention deficit/hyperactivity disorder (AHDH) in children on a variety of outcomes. A secondary objective was to determine the influence of specific

2006 DARE.

228. Comparing the efficacy of medications for ADHD using meta-analysis

Comparing the efficacy of medications for ADHD using meta-analysis Comparing the efficacy of medications for ADHD using meta-analysis Comparing the efficacy of medications for ADHD using meta-analysis Faraone S V, Biederman J, Spencer T J, Aleardi M CRD summary The authors concluded that the greater efficacy found for stimulants compared with nonstimulants in children with attention-deficit/hyperactivity disorder (ADHD) needs to be interpreted with caution in view of the impact of potential (...) confounding factors. There were limitations in the review process, but the authors’ conclusion appears appropriately cautious given the lack of head-to-head comparisons of different classes of ADHD drugs. Authors' objectives To compare the efficacy of drug treatments for attention-deficit/hyperactivity disorder (ADHD) in youths. Searching MEDLINE, PREMEDLINE, PubMed, ERIC, CINAHL, the Cochrane CENTRAL Register, e-psyche and Social Science Abstracts were searched for studies published after 1979

2006 DARE.

229. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 National (...) Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13. London: National Institute for Health and Clinical Excellence

2006 Health Technology Assessment (HTA) Database.

230. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technology Assessment 2006; 10(23): 1-162 Authors' objectives

The aim of this document is to assess the clinical and cost-effectiveness of oral methylphenidate hydrochloride (MPH), dexamfetaminesulphate (DEX) and atomoxetine (ATX) in children and adolescents (<18 years of age) diagnosed with attention deficit hyperactivity disorder (ADHD) (including hyperkinetic disorder).

attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model

2006 Health Technology Assessment (HTA) Database.

231. Adult attention deficit hyperactivity disorder is common among people in the US who are male, white, previously married, or not employed

Adult attention deficit hyperactivity disorder is common among people in the US who are male, white, previously married, or not employed Adult attention deficit hyperactivity disorder is common among people in the US who are male, white, previously married, or not employed | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adult attention deficit hyperactivity disorder is common among people in the US who are male, white, previously

2006 Evidence-Based Mental Health

232. The experiences of children and adolescents living with ADHD were reflected in 6 themes Full Text available with Trip Pro

Slimmer , RN, PhD Statistics from Altmetric.com Kendall J, Hatton D, Beckett A, et al . Children’s accounts of attention-deficit/hyperactivity disorder. ANS Adv Nurs Sci 2003 ; 26 : 114 –30. Q What are the experiences of children and adolescents living with attention deficit hyperactivity disorder (ADHD)? DESIGN Qualitative study. SETTING Portland, Oregon and San Diego, California, USA. PATIENTS 39 children and adolescents with ADHD (age range 6–17 y; 67% boys; 38% African-American, 33% Hispanic (...) “weird” or “whacko.” CONCLUSION The experiences of children and adolescents with attention deficit hyperactivity disorder (ADHD) were reflected in 6 themes: problems in thinking, behaving, and feeling; meaning and identity; taking pills; the importance of Mom; causes of ADHD; and differences associated with ethnicity or race. Commentary More children are referred to mental health clinics for ADHD than for any other psychiatric or behavioural problem. The qualitative study by Kendall et al provides

2005 Evidence-Based Nursing

233. Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents. Full Text available with Trip Pro

Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents. Attention-deficit hyperactivity disorder (ADHD) is diagnosed in between 3% and 7% of school-age children and consists of the core symptoms of inattention, impulsivity and hyperactivity. Children are often treated with medication, usually stimulant medication such as methylphenidate. Stimulant medication has been found to be effective for alleviating ADHD symptoms, at least (...) 2004), and Sociological Abstracts (Sociofile) (1963 to April 2004). Hand searches of relevant journals and bibliographies were also conducted and experts in the field were contacted for further information.Included studies were randomised controlled trials investigating the efficacy of behavioural family therapy, cognitive behavioural family therapy, or functional family therapy for children with ADHD or ADD (Attention Deficit Disorder).Studies were evaluated for methodological quality

2005 Cochrane

234. Attention-deficit hyperactivity disorder. (Abstract)

Attention-deficit hyperactivity disorder. Attention-deficit hyperactivity disorder (ADHD) is a disorder of inattention, impulsivity, and hyperactivity that affects 8-12% of children worldwide. Although the rate of ADHD falls with age, at least half of children with the disorder will have impairing symptoms in adulthood. Twin, adoption, and molecular genetic studies show ADHD to be highly heritable, and other findings have recorded obstetric complications and psychosocial adversity (...) as predisposing risk factors. Converging evidence from animal and human studies implicates the dysregulation of frontal-subcortical-cerebellar catecholaminergic circuits in the pathophysiology of ADHD, and molecular imaging studies suggest that abnormalities of the dopamine transporter lead to impaired neurotransmission. Studies during the past decade have shown the safety and effectiveness of new non-stimulant drugs and long-acting formulations of methylphenidate and amfetamine. Other investigations have

2005 Lancet

235. Review: stimulant pharmacotherapy for children with ADHD is associated with a reduced risk of later substance abuse disorder Full Text available with Trip Pro

Aetiology Review: stimulant pharmacotherapy for children with ADHD is associated with a reduced risk of later substance abuse disorder Free Peter S Jensen , MD Statistics from Altmetric.com ( 2003 ) Pediatrics 111 , 179 . Wilens TE, Faraone SV, Biederman J, et al. . Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. . ; . : . –85 . Question In children with attention deficit hyperactivity disorder (ADHD), what (...) more influence than any other on the pooled estimate. Conclusion In children who had childhood attention deficit hyperactivity disorder, the use of stimulant pharmacotherapy is associated with a reduced risk of developing substance use disorder in adolescence or adulthood. Commentary The review by Wilens et al is a careful analysis of the highest quality available, longitudinal studies to assess the possible association between stimulant treatment and later risk of substance abuse among children

2004 Evidence-Based Medicine

236. Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies

Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies Cohen-Zion M, Ancoli-Israel S CRD summary This review assessed the effects of psychostimulants on sleep (...) in children with attention-deficit hyperactivity disorder. The authors found limited evidence to suggest a possible increase in some sleep complaints, but concluded that further studies are required. Despite some methodological limitations to this review, the authors' cautious conclusions and recommendation for further research appear reasonable. Authors' objectives To assess the relationship between attention-deficit hyperactivity disorder (ADHD) symptomatology and sleep, and the effects

2004 DARE.

237. The status of empirical support for treatments of attention deficits

The status of empirical support for treatments of attention deficits Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

238. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder

Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

239. Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD

, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of methylphenidate (MPH) versus amphetamine/dextroamphetamine mixed salts (AMP/DEX) as first-line agents for the treatment of attention deficit hyperactivity disorder (ADHD) was studied. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of male children aged (...) in the review No study designs were reported. However, the studies used to assess efficacy rates included those that assessed response to therapy at a minimum of 1 month and a maximum of 8 weeks. Sources searched to identify primary studies HealthSTAR and MEDLINE were searched for primary studies using the keywords "attention deficit hyperactivity disorder", "methylphenidate", "amphetamine / dextroamphetamine mixed salts", "adverse events", "compliance rates", "school administration", "economic burden

2004 NHS Economic Evaluation Database.

240. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. (Abstract)

Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Results of structural brain imaging studies of patients with attention-deficit hyperactivity disorder have shown subtle reductions in total brain volume and in volumes of the right frontal lobe and caudate nucleus. Although various conventional volumetric and voxel-based methods of image analysis have been used in these studies, regional brain size and grey-matter abnormalities have not yet been (...) mapped over the entire cortical surface in patients with this disorder. We aimed to map these features in patients with attention-deficit hyperactivity disorder.We used high-resolution MRI and surface-based, computational image analytic techniques to map regional brain size and grey-matter abnormalities at the cortical surface in a group of 27 children and adolescents with attention-deficit hyperactivity disorder and 46 controls, who were group-matched by age and sex.Abnormal morphology was noted

2003 Lancet